Twist Bioscience (Twist Bioscience) Cash And Cash Equivalents : $266.3 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Cash And Cash Equivalents?

Twist Bioscience's quarterly cash and cash equivalents declined from Jun. 2023 ($307.46 Mil) to Sep. 2023 ($286.47 Mil) but then stayed the same from Sep. 2023 ($286.47 Mil) to Dec. 2023 ($266.27 Mil).

Twist Bioscience's annual cash and cash equivalents declined from Sep. 2021 ($465.83 Mil) to Sep. 2022 ($378.69 Mil) and declined from Sep. 2022 ($378.69 Mil) to Sep. 2023 ($286.47 Mil).

Twist Bioscience Cash And Cash Equivalents Historical Data

The historical data trend for Twist Bioscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Cash And Cash Equivalents Chart

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash And Cash Equivalents

Get a 7-Day Free Trial

46.74

93.67

465.83

378.69

286.47

Twist Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															316.68	315.20	307.46	286.47	266.27

Twist Bioscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Twist Bioscience (NAS:TWST) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Twist Bioscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Twist Bioscience (Twist Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (NAS:TWST) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Executives

Robert F. Werner	officer: Chief Accounting Officer	2500 FABER PLACE, PALO ALTO CA 94303
Dennis Cho	officer: See Remarks	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Melissa A. Starovasnik	director	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jan Johannessen	director	5555 NE MOORE CT., HILLSBORO OR 97124
William Banyai	director, officer: Chief Operating Officer	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Paula Green	officer: VP of Human Resources	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
James M Thorburn	officer: Chief Financial Officer	C/O ZILOG INC, 532 RACE STREET, SAN JOSE CA 95126
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Robert Chess	director
Patrick John Finn	officer: VP of Sales and Marketing	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Emily M. Leproust	director, officer: President & CEO	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Patrick Weiss	officer: VP of Operations	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Keith Crandell	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kevin Bruce Yankton	officer: Chief Accounting Officer	1678 S. PIONEER ROAD, SALT LAKE CITY UT 84104
Mark Daniels	officer: Chief Compliance Officer & GC	C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158